Side-by-side · Research reference
PEG-MGFvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED2/69 cited
BFDA-ApprovedFlagship15/53 cited
PEG-MGF
IGF-1Ec Splice Variant · PEGylated
~2 hrHalf-life (PEG)
~7 minNative MGF t½
IGF-1EcSplice variant
SQ · Research Protocol
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
PEG-MGF
Semaglutide
Primary target
IGF-1 receptor on muscle satellite cells and myocytes
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Satellite cell activation, muscle fiber repair, localized hypertrophy signaling
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Partially bypassed — does not require hepatic IGF-1 synthesis
Glucose-dependent insulin release preserves physiological feedback
Origin
IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
Unknown — no long-term human immunogenicity data
—
02Dosage Protocols
Parameter
PEG-MGF
Semaglutide
Research dose range
100–200 mcg
Extrapolated from animal models; no validated human protocols.
—
Frequency
Post-training or daily
Timing to match endogenous MGF pulse post-exercise.
Once weekly, same day each week
Half-life
~2 hours (PEGylated)
Native MGF: ~7 min; PEGylation extends circulation.
~7 days (168 h)WEGOVY (semaglutide) injection 2021
Evidence basis
Animal / mechanistic
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Reconstitution
Sterile bacteriostatic water
Lyophilized form; store reconstituted at 2–8 °C.
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
PEG molecular weight
Typically 5–30 kDa
Higher MW = longer t½, greater steric hindrance.
—
Timing
Within 30–60 min post-training
Aligns with endogenous MGF window.
Any time of day, with or without food
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Discontinuation results in weight regain.
03Metabolic / Fat Loss Evidence
Parameter
PEG-MGF
Semaglutide
Primary target
Muscle tissue (satellite cells, myocytes) — not adipose-specific
—
Indirect metabolic effect
IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015
Mechanism distinct from direct lipolytic peptides.
—
Body composition
Lean mass preservation / hypertrophy focus
—
Fat loss evidence
No direct human or animal RCT data for PEG-MGF-driven fat reduction
—
04Side Effects & Safety
Parameter
PEG-MGF
Semaglutide
Injection site reaction
Erythema, induration (common with SQ peptides)
Mild erythema, pruritus
Hypoglycemia risk
IGF-1 axis activation can lower blood glucose
—
IGF-1R overstimulation
Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure
—
Fluid retention
Possible with IGF-1 pathway activation (dose-dependent)
—
PEG accumulation
Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment
—
Antibody formation
PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)
—
Cancer risk
IGF-1 axis stimulation contraindicated in active malignancy
—
Human safety data
Absent — no published human trials for PEG-MGF
—
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
PEG-MGF
- ·Active malignancy or history of cancer (IGF-1R proliferative signaling)
- ·Known hypersensitivity to PEGylated compounds
- ·Pregnancy / lactation (no reproductive toxicity data)
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
PEG-MGF
- ·Diabetes (monitor glucose closely)
- ·Renal impairment (PEG clearance reduced)
- ·Retinopathy (IGF-1 axis effects on vascular proliferation)
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
PEG-MGF
Semaglutide
1. Reconstitution
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
PEG-MGF
+ BPC-157
ModerateBPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
- PEG-MGF
- 100–200 mcg SQ post-training
- BPC-157
- 250–500 mcg SQ or oral, twice daily
- Duration
- 4–6 weeks (injury-dependent)
- Primary benefit
- Accelerated muscle and connective tissue repair, enhanced recovery
+ TB-500
StrongTB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
- PEG-MGF
- 100–200 mcg SQ post-training
- TB-500
- 2–5 mg SQ, 2× per week (loading), then weekly
- Timing
- Stagger injections by 6–12 hours
- Primary benefit
- Maximal satellite cell recruitment and myogenic differentiation, injury repair
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)